Cost of whole genome sequencing for non-typhoidal Salmonella enterica

PLoS One. 2021 Mar 19;16(3):e0248561. doi: 10.1371/journal.pone.0248561. eCollection 2021.

Abstract

Background: While whole genome sequencing (WGS) may be more expensive than traditional testing and polymerase chain reaction (PCR), simple cost comparisons ignore the potential for WGS to reduce the societal costs of non-typhoidal Salmonella enterica through public health action to prevent illness.

Methods: We determined how many cases the use of WGS data would need to prevent to be cost-equal to serotyping and MLVA, or culture independent testing based on PCR in Australia. We then examined the costs and cost-savings of current typing methods compared with WGS in outbreak scenarios.

Results: A median of 275 (90% CrI -55-775) or 1.9% (90% CrI -0.4%-5.4%) of notified serotyped Salmonella cases would need to be prevented for WGS to be cost-equal to current typing methods and 1,550 (90% CrI 820-2,725) or 9.6% of all notified Salmonella cases would need to be prevented to be cost-equal to PCR. WGS is likely to result in cost savings in prolonged outbreaks, where data can support earlier public health action.

Conclusions: Despite currently having a higher cost per isolate, routine WGS of Salmonella was no more expensive than existing typing methods or PCR where >2% of illness was averted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Australia / epidemiology
  • Disease Outbreaks / prevention & control*
  • Humans
  • Salmonella Infections* / microbiology
  • Salmonella Infections* / prevention & control
  • Salmonella enterica* / genetics
  • Salmonella enterica* / isolation & purification
  • Serotyping / economics*
  • Whole Genome Sequencing / economics*

Grants and funding

Laura Ford is supported by an Australian Government Research Training Program (RTP) Scholarship. The National Health & Medical Research Council provided research fellowship funding for Martyn D. Kirk (APP1145997), Deborah A. Williamson (APP1123854) and Vitali Sintchenko (APP1123879). Jennifer M.B. Robson is employed by Sullivan Nicolaides Pathology. These funders provided support in the form of salaries for authors LF, MDK, DAW, VS and JMBR, but did not have any additional role in the study design, data collection and analysis, decision to published, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.